Recent News

• 06.10.2026 - Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
• 05.07.2026 - Celldex Reports First Quarter Financial Results and Provides Corporate Update
• 04.13.2026 - Celldex to Present at Upcoming Investor Conference
• 04.06.2026 - Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
• 04.02.2026 - Celldex Announces Pricing of $300 Million Public Offering of Common Stock
• 04.01.2026 - Celldex Announces Proposed Public Offering of Common Stock

Recent Filings

• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.07.2026 - 8-K Current report
• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - EX-99.1 EX-99.1
• 05.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.29.2026 - DEF 14A Other definitive proxy statements
• 04.29.2026 - ARS Annual Report to Security Holders